Rheumatology Medical News about Vasculitis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs
Journal of Clinical Endocrinology and Metabolism, 06/17/09

Noh JY et al. – Study reports that the time of onset of MPO-ANCA-associated vasculitis and the dose at onset varied. The severity and number of organs involved were not correlated with the MPO-ANCA titre, warranting the need for vigilance even when the titre is weakly positive.

Methods

An analysis of pts with MPO-ANCA-associated vasculitis to determine:
- Time of onset
- Drug and dose taken
- Clinical symptoms
- Relationship between the clinical symptoms and the MPO-ANCA titre, and the incidence
92 pts in whom the adverse reaction of MPO-ANCA-associated vasculitis was reported were analysed

Results

Organ failure reported as:
- 41/92 (44.6%) pts had single-organ failure
- 34.8% had two-organ failure
- 14.1% had three-organ failure
- 2.2% had four-organ failure
- Number of organs involved was unknown in 4.3% of pts
Median time of onset was 42 mo after starting drug treatment
Median dose at onset of MPO-ANCA-associated vasculitis was 15 mg/d for methimazole, and 200 mg/d for propylthiouracil
Severity and number of organs involved were not correlated with the MPO-ANCA titre
Incidence was between 0.53 and 0.79 pts per 10,000
Ratio of the estimated incidences for methimazole and propylthiouracil was 1:39.2